The Incretins Y A E G T F I S D Y S I A M D K I H Q Q D F V N W L L A Q K G K K N D W K H NQ T I GIP : Gastric Inhibitory Polypeptide Glucose-Dependent Insulinotropic Polypeptide H A E G T F T S D V S S Y L E G Q A A K E F I A W L V K G R G GLP-1 : Glucagon-Like Peptide 1 Amino acids shown in yellow are homologous with the structure of glucagon. Courtesy of Daniel Drucker, MD. Drucker. Diabetes Care. 2003;26:2929.
Enhances responsiveness of the cell to glucose Improves the dynamics of the insulin response Stimulates -cell transcription Reduces -cell apoptosis Effects of GLP-1 on Cells Ahrén. Diabetes Care. 2003;26:2860. Farilla. Endocrinology. 2002;143:4397.
AMIGO Trial Results Acronym for AC2993 (early name for exenatide) Diabetes Management for Improving Glucose Outcomes –April 2005 approval of exenatide for treatment of T2DM based on results of these 3 trials Exenatide compared with placebo in the following groups: –AMIGO 1: Patients taking metformin –AMIGO 2: Patients taking a sulfonylurea –AMIGO 3: Patients taking combination therapy (metformin + sulfonylurea) DeFronzo. Diabetes Care. 2005;28:1092. Buse. Diabetes Care. 2004;27:2628. Kendall. Diabetes Care. 2005;28:1083.